Berra Yazar-Klosinski, Ph.D., the chief scientific officer of MAPS Public Benefit Corporation (MAPS PBC), is responsible for regulatory affairs, pharmacovigilance, medical affairs, pharmacology and toxicology. She began working on the clinical development of MDMA-assisted therapy when she joined MAPS in 2009 and has been with MAPS PBC since its inception in 2014. Over the years Berra has supported the various stages of clinical development and regulatory affairs, while authoring numerous publications on MDMA-assisted therapy, LSD-assisted psychotherapy, cannabis, and ibogaine. She has developed a strong track record of success with FDA, EMA and other regulatory agencies. Prior to MAPS PBC, Berra gained clinical research experience working in laboratories at Geron Corporation and Millennium Pharmaceuticals. She earned her B.S. in Biology with a minor in Drama from Stanford University and her Ph.D. in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz.